Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score-Reference-Cited by-同舟云学术

Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score

Published:2020-04-01 Issue:8 Volume:277 Page:2341-2347
ISSN:0937-4477
Container-title:European Archives of Oto-Rhino-Laryngology
language:en
Short-container-title:Eur Arch Otorhinolaryngol

Author:

Ueki Yushi^ORCID,Takahashi Takeshi,Ota Hisayuki,Shodo Ryusuke,Yamazaki Keisuke,Horii Arata

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Otorhinolaryngology

Link

http://link.springer.com/content/pdf/10.1007/s00405-020-05945-5.pdf

Reference17 articles.

1. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. https://doi.org/10.1056/NEJMoa1602252

2. Ferris RL, Blumenschein G Jr, Fayette J et al (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45–51. https://doi.org/10.1016/j.oraloncology.2018.04.008

3. Jie HB, Schuler PJ, Lee SC et al (2015) CTLA-4+ regulatory T cells increased in Cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75:2200–2210. https://doi.org/10.1158/0008-5472.CAN-14-2788

4. Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136

5. Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374–378. https://doi.org/10.1001/jamaoncol.2017.2925

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab;Investigational New Drugs;2023-08-21

2. Site of distant metastasis affects the prognosis with recurrent/metastatic head and neck squamous cell carcinoma patients treated with Nivolumab;International Journal of Clinical Oncology;2023-07-08

3. Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta‐analysis;Head & Neck;2023-05-10

4. Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis;European Journal of Cancer;2023-05

5. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma;Oral Diseases;2023-01-04